✦ LIBER ✦

An EORTC phase I study of capecitabine (Xeloda®) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer

✍ Scribed by H. Bonnefoi; L. Biganzoli; L. Mauriac; T. Cufer; P. Schaefer; G. Atalay; M. Piccart

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An EORTC phase I study of epirubicin in

✍ H Bonnefoi; L Biganzoli; T Cufer; L Mauriac; A Hamilton; P Schaefer; M Piccart 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 90 KB

Cyclophosphamide (C) - Epirubicine (E) -

✍ L. Biganzoli; H. Bonnefoi; L. Mauriac; T. Cufer; E. Ngalula Kabanga; D. Hébert; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 173 KB

Final Results of a Randomized Phase III

✍ Therasse, P. 📂 Article 📅 2003 🏛 American Society of Clinical Oncology 🌐 English ⚖ 107 KB

An European Organisation for Research an

✍ Bonnefoi, H.; Zaman, K.; Debled, M.; Fiche, M.; Fournier, M.; Nobahar, M.; Pierg 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 397 KB